DRRX DURECT CORP US FDA Inspections 8-K Filing 2024 - Other Special Situation DURECT Corp announced that the FDA has granted Breakthrough Therapy designation to larsucosterol for the treatment of severe alcohol-associated hepatitis.Get access to all SEC 8-K filings of the DURECT CORP